Oct 08, 2021 · “qulipta provides a simple oral treatment option specifically developed to prevent migraine attacks and target cgrp, which is believed to be crucially involved in migraine in many patients,” said.... More than 10% of people worldwide suffer from migraines. It is commonly seen within the age group of 20-50 years. In India, 1-4 out of 8 people are known to suffer from migraine. Before you call your pain another headache, you must read on to understand how migraines are distinct from headaches. Many people confuse migraines with headaches. Nurtec ODT was approved as a preventive treatment for episodic migraine in June 2021. And Qulipta was ... received FDA approval in September 2021 only as a preventive medication for episodic migraine. The drug, Qulipta, which AbbVie will launch in early October, will enter a crowded market for migraine prevention drugs such as Eli Lilly's Emgality, Amgen Inc's Aimovig and Biohaven Pharmaceutical.